The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Chronic Fatigue Syndrome: Why Myalgic Encephalomyelitis Is the Preferred Term and More

Chronic Fatigue Syndrome: Why Myalgic Encephalomyelitis Is the Preferred Term and More

October 17, 2017 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Tashatuvango / shutterstock.com

Tashatuvango / shutterstock.com

CHICAGO—Joseph Breen, PhD, program officer at the National Institutes of Health in Bethesda, Md., opened the chronic fatigue syndrome (CFS) session at the Federation of Clinical Immunology Societies (FOCIS) 2017 meeting by asking presenters to describe the current state of the science to the key immunology stakeholders gathered in the room. The hope was that the presentations would stimulate new approaches to decipher the mechanistic and immunological underpinnings of myalgic encephalomyelitis (ME)/CFS, as well as open new avenues for clinical solutions.

You Might Also Like
  • A Rose by Any Other Name: Why clinicians & patients prefer the term myalgic encephalomyelitis & other updates on chronic fatigue syndrome
  • Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Redefined
  • Scientists May Be Closer to A Blood Test for Chronic Fatigue Syndrome
Explore This Issue
October 2017
Also By This Author
  • Dysbiosis of Gut, But Not Ocular Microbiome, Associated with Sjögren’s Syndrome

Elizabeth Unger, MD, PhD, chief of the chronic viral diseases branch of the Centers for Disease Control and Prevention (CDC) agreed with this call to action, stating, “It is very, very important that we have excellent scientists investigating this illness.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

What’s in a Name?

Researchers coined the name chronic fatigue syndrome in 1988 at the time of the first case definition, and the name has remained attached to the disease. Now, however, many patients and clinicians feel the name chronic fatigue syndrome trivializes the medical condition and they choose, instead, to use the name ME. CFS is also known as systemic exertion intolerance disease (SEID).

Public Health Problem

Dr. Unger described ME/CFS as a serious and long-term illness that affects many systems throughout the body. Patients who live with ME/CFS are unable to function in the same way they did before they became ill.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“One of the problems clinicians have is that the patients can look healthy when they walk into the office,” she explained, adding that, “It’s important they know this is a biological illness. This is not a mental illness.”

At least 1 million Americans have ME/CFS. This translates into a prevalence rate of 0.2%–0.7%. Unfortunately, only 20% of patients have been diagnosed. Patients, families and society bear the significant cost of the disease, which is estimated to be $9–14 billion annually in direct medical costs.

Although ME/CFS affects all populations, it is most prevalent in individuals aged 40–50 years. Infectious risk factors for ME/CFS are notable, but it is unclear if these infections are a cause or effect of ME/CFS. Non-infectious risk factors for ME/CFS include stress from physical trauma and adverse events. Some patients with ME/CFS have abnormal sleep patterns, but there are no consistent sleep abnormalities.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“The syndrome looks like a ‘sickness behavior’ triggered by cytokines after infection,” acknowledged Dr. Unger.

ME/CFS presents multiple challenges to the medical system. Firstly, it has no diagnostic test. Instead diagnosis relies on case definition, which is often inadequate to describe the disease. In 2015, the Institute of Medicine proposed a clinical case definition for ME/CFS. The new criteria include a substantial reduction or impairment in the ability to engage in pre-illness levels of occupational, educational, social or personal activities; post-exertional malaise; unrefreshing sleep; and at least one of the two symptoms: cognitive impairment or orthostatic intolerance.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports Tagged With: autoinflammatory disease, case report, Clinical, Diagnosis, fellow, fever, genetic, molecular, outcome, polyarthritis, rash, Research, Rheumatic Disease, rheumatologist, rheumatology, symptom, systemic inflammatory syndrome, Testing, TreatmentIssue: October 2017

You Might Also Like:
  • A Rose by Any Other Name: Why clinicians & patients prefer the term myalgic encephalomyelitis & other updates on chronic fatigue syndrome
  • Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Redefined
  • Scientists May Be Closer to A Blood Test for Chronic Fatigue Syndrome
  • Molecular Profile Hints at Inflammatory Processes in Chronic Fatigue

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.